CSN5i-3-NEG | CAS#unknown | CSN5i-3 negative control

MedKoo Cat#: 466245 | Name: CSN5i-3-NEG

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CSN5i-3-NEG is the negative control for CSN5i-3.

Chemical Structure

CSN5i-3-NEG

CAS#unknown

Theoretical Analysis

MedKoo Cat#: 466245

Name: CSN5i-3-NEG

CAS#: unknown

Chemical Formula: C28H29F2N5O2

Exact Mass: 505.2289

Molecular Weight: 505.57

Elemental Analysis: C, 66.52; H, 5.78; F, 7.52; N, 13.85; O, 6.33

Price and Availability

Size	Price	Availability	Quantity
2mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

CSN5i-3-NEG; CSN5i3-NEG; CSN5i 3-NEG; CSN5i-3NEG; CSN5i-3 NEG; CSN5i3NEG; CSN5i 3 NEG;

IUPAC/Chemical Name

3-(difluoromethyl)-N-(6-((5R,6R)-6-hydroxy-6,7,8,9-tetrahydro-5H-imidazo[1,5-a]azepin-5-yl)-[1,1'-biphenyl]-3-yl)-1-isopropyl-1H-pyrazole-5-carboxamide

InChi Key

ANNKHJQLDMGQFM-CLJLJLNGSA-N

InChi Code

InChI=1S/C28H29F2N5O2/c1-17(2)35-24(14-23(33-35)27(29)30)28(37)32-19-11-12-21(22(13-19)18-7-4-3-5-8-18)26-25(36)10-6-9-20-15-31-16-34(20)26/h3-5,7-8,11-17,25-27,36H,6,9-10H2,1-2H3,(H,32,37)/t25-,26-/m1/s1

SMILES Code

CC(C)N1N=C(C=C1C(NC2=CC(C3=CC=CC=C3)=C(C=C2)[C@@H]4[C@H](O)CCCC5=CN=CN45)=O)C(F)F

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	To be determined	50.6	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 505.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Mazzu YZ, Liao YR, Nandakumar S, Jehane LE, Koche RP, Rajanala SH, Li R, Zhao H, Gerke TA, Chakraborty G, Lee GM, Nanjangud GJ, Gopalan A, Chen Y, Kantoff PW. Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer. Oncogene. 2022 Jan;41(5):671-682. doi: 10.1038/s41388-021-02118-4. Epub 2021 Nov 20. PMID: 34802033. 2: Mamidi MK, Samsa WE, Danielpour D, Chan R, Zhou G. The transcription co- factor JAB1/COPS5, serves as a potential oncogenic hub of human chondrosarcoma cells in vitro. Am J Cancer Res. 2021 Oct 15;11(10):5063-5075. PMID: 34765312; PMCID: PMC8569363. 3: Harshuk-Shabso D, Castel N, Israeli R, Harari S, Pick E. Saccharomyces cerevisiae as a Toolkit for COP9 Signalosome Research. Biomolecules. 2021 Mar 25;11(4):497. doi: 10.3390/biom11040497. PMID: 33806190; PMCID: PMC8065851. 4: Samsa WE, Mamidi MK, Bashur LA, Elliott R, Miron A, Chen Y, Lee B, Greenfield EM, Chan R, Danielpour D, Zhou G. The crucial p53-dependent oncogenic role of JAB1 in osteosarcoma in vivo. Oncogene. 2020 Jun;39(23):4581-4591. doi: 10.1038/s41388-020-1320-6. Epub 2020 May 10. PMID: 32390003; PMCID: PMC7274902. 5: Majolée J, Pronk MCA, Jim KK, van Bezu JSM, van der Sar AM, Hordijk PL, Kovačević I. CSN5 inhibition triggers inflammatory signaling and Rho/ROCK- dependent loss of endothelial integrity. Sci Rep. 2019 May 31;9(1):8131. doi: 10.1038/s41598-019-44595-4. PMID: 31148579; PMCID: PMC6544660. 6: Xiao H, Claret FX, Shen Q. The novel Jab1 inhibitor CSN5i-3 suppresses cell proliferation and induces apoptosis in human breast cancer cells. Neoplasma. 2019 May 23;66(3):481-486. doi: 10.4149/neo_2018_181016N772. Epub 2019 Mar 7. PMID: 30868895. 7: Kumar V, Naumann M, Stein M. Computational Studies on the Inhibitor Selectivity of Human JAMM Deubiquitinylases Rpn11 and CSN5. Front Chem. 2018 Oct 9;6:480. doi: 10.3389/fchem.2018.00480. PMID: 30356695; PMCID: PMC6189316. 8: Zhang H, Zhong A, Sun J, Chen M, Xie S, Zheng H, Wang Y, Yu Y, Guo L, Lu R. COPS5 inhibition arrests the proliferation and growth of serous ovarian cancer cells via the elevation of p27 level. Biochem Biophys Res Commun. 2017 Nov 4;493(1):85-93. doi: 10.1016/j.bbrc.2017.09.070. Epub 2017 Sep 15. PMID: 28919423. 9: Schlierf A, Altmann E, Quancard J, Jefferson AB, Assenberg R, Renatus M, Jones M, Hassiepen U, Schaefer M, Kiffe M, Weiss A, Wiesmann C, Sedrani R, Eder J, Martoglio B. Targeted inhibition of the COP9 signalosome for treatment of cancer. Nat Commun. 2016 Oct 24;7:13166. doi: 10.1038/ncomms13166. PMID: 27774986; PMCID: PMC5078989.